Welcome Guest
Home > Clinical Breast Cancer > Volume 1 |  Issue 3

Table of Contents

Volume 1 |  Issue 3

Publication Date: October 2000
  • Abstract Abstract
  • Full Text No Access
  • Full Text Pay-Per View
  • Full Text Full Text
  • Add to Cart Add to Cart


Editorial
Page Number of this Article in the Print Version
176		 The Future of Clinical Research in Breast Cancer: Challenges
George W. Sledge, Jr
  • Abstract
  • No Access
  • Add to Cart
Meeting Highlights
Page Number of this Article in the Print Version
180-185		 Highlights From: 36th Annual ASCO Meeting, New Orleans, LA, May 2000
Amy D’Orazio
  • Abstract
  • No Access
  • Add to Cart
Researches in Brief
Page Number of this Article in the Print Version
189-190		 Benefit of the Addition of Paclitaxel to Standard Chemotherapy with 5-Fluorouracil/Doxorubicin/Cyclophosphamide in Patients with Operable Breast Cancer
Amy D’Orazio
  • Abstract
  • No Access
  • Add to Cart
Page Number of this Article in the Print Version
191-192		 High-Dose Adjuvant Chemotherapy for Patients with High-Risk Breast Cancer: Efficacy is Still an Open Question
Amy D’Orazio
  • Abstract
  • No Access
  • Add to Cart
Page Number of this Article in the Print Version
193-194		 Effect of Estrogen Suppression in Premenopausal Patients with Early Breast Cancer by Goserelin (ZIPP Trial)
Amy D’Orazio
  • Abstract
  • No Access
  • Add to Cart
Comprehensive Review
Page Number of this Article in the Print Version
197-209		 High-Dose Chemotherapy with Hematopoietic Stem-Cell Transplantation for Breast Cancer: Current Status, Future Trends
Filippo Montemurro, Naoto T. Ueno, Gabriela Rondón, Massimo Aglietta, Richard E. Champlin
  • Abstract
  • No Access
  • Add to Cart
Commentary
Page Number of this Article in the Print Version
210		 Commentary on “High-Dose Chemotherapy with Hematopoietic Stem-Cell Transplantation for Breast Cancer: Current Status, Future Trends”
Andrew D. Seidman
  • Abstract
  • No Access
  • Add to Cart
Comprehensive Reviews
Page Number of this Article in the Print Version
211-216		 Exemestane: A Novel Aromatase Inactivator for Breast Cancer
Stephanie A. Jones, Stephen E. Jones
  • Abstract
  • No Access
  • Add to Cart
Page Number of this Article in the Print Version
217-225		 Clinical Relevance of Occult Metastatic Cells in the Bone Marrow of Patients with Different Stages of Breast Cancer
Wolfgang Janni, Dorothea Rjosk, Stephan Braun
  • Abstract
  • No Access
  • Add to Cart
Original Contribution
Page Number of this Article in the Print Version
226-232		 Phase II Trial of Gemcitabine/Doxorubicin/Paclitaxel Administered Every Other Week in Patients with Metastatic Breast Cancer
Pedro Sánchez-Rovira, Ana Jaén, Encarnación González, Ignacio Porras, Maria Rosario Dueñas, Begoña Medina, Nicolás Mohedano, Margarita Fernández, Maximiliano Martos, Ana Lozano
  • Abstract
  • No Access
  • Add to Cart
Translational Medicine
Page Number of this Article in the Print Version
233-240		 A Study of the Value of p53, HER2, and Bcl-2 in the Prediction of Response to Doxorubicin and Paclitaxel as Single Agents in Metastatic Breast Cancer: A Companion Study to EORTC 10923
A. Hamilton, D. Larsimont, R. Paridaens, M. Drijkoningen, M. van de Vijver, P. Bruning, A. Hanby, S. Houston, I. Treilleux, J. P. Guastalla, A. Van Vreckem, R. Sylvester, M. Piccart
  • Abstract
  • No Access
  • Add to Cart
Commentary
Page Number of this Article in the Print Version
241-242		 Commentary on “A Study of the Value of p53, HER2, and Bcl-2 in the Prediction of Response to Doxorubicin and Paclitaxel as Single Agents in Metastatic Breast Cancer: A Companion Study to EORTC 10923”
Vered Stearns, Daniel F. Hayes
  • Abstract
  • No Access
  • Add to Cart
Images in Breast Cancer
Page Number of this Article in the Print Version
243-244		 Cytopathology of Metastatic Breast Cancer
Harvey Cramer
  • Abstract
  • No Access
  • Add to Cart